The planned sample size was 500 patients based on the estimated number of patients who were anticipated to receive treatment with prasugrel and on enrollment feasibility. We enrolled consecutive patients in each institution to avoid patient selection bias. For each of the safety and efficacy variables, a point estimate and its 95% confidence interval (CI) were calculated.